#1 Clinical Trials Search in Europe

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

3 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called baricitinib on patients with COVID-19, which is caused by the SARS-CoV-2 virus. The study aims to understand how this medication, when added to the standard care, affects the progression of the disease in hospitalized patients who are immunocompromised, meaning their immune system is weakened. The trial will compare the effects of baricitinib to a placebo, which is a substance with no active medication, to see if there is a difference in outcomes.

The purpose of the study is to determine if baricitinib can help reduce the risk of death in patients with severe or critical COVID-19. Participants in the study will receive either the medication or a placebo, and their health will be monitored to see how the disease progresses. The study will look at whether the medication can prevent the disease from getting worse and if it can help patients recover more quickly.

Throughout the study, participants will be closely observed to track their recovery and any changes in their condition. The trial will also assess various health markers to understand the impact of the treatment. This research is part of a larger effort to find effective treatments for COVID-19 and improve outcomes for patients with this disease.

1 joining the study

Upon joining the study, you will be asked to provide informed consent. This means you agree to participate after understanding the study’s purpose and procedures.

You will need to confirm that you are at least 18 years old and have a laboratory-confirmed SARS-CoV-2 infection that is not more than 14 days old.

2 hospital admission

You must be admitted to the hospital to participate in this study. The study focuses on patients with moderate to severe COVID-19 symptoms.

Your condition will be assessed to determine if you meet the criteria for moderate or severe disease.

3 treatment assignment

You will be randomly assigned to receive either the medication baricitinib or a placebo. A placebo is a substance with no active medication, used to compare effects.

The medication is administered as a 2 mg film-coated tablet taken orally.

4 medication administration

You will take the assigned tablet once daily. The duration of administration will depend on your response to the treatment and the study’s protocol.

Your health will be monitored closely during this period to observe any changes in your condition.

5 monitoring and assessments

Throughout the study, your health will be regularly monitored. This includes checking inflammatory markers and other health indicators.

You may undergo various tests, such as blood tests and oxygen level assessments, to track your progress.

6 end of study participation

Your participation in the study will conclude after a specified period, or if your condition changes significantly.

The study aims to determine the effect of the treatment on disease progression and survival rates.

Who Can Join the Study?

  • Must be 18 years or older.
  • Must have a laboratory-confirmed SARS-CoV-2 infection (new infection or reinfection) confirmed by a PCR test within the last 14 days.
  • Must be admitted to the hospital.
  • Must provide informed consent to participate, or have a legally authorized representative provide consent.
  • Must have a severe or critical disease state, which means at least one of the following:
    • Oxygen level (SpO2) less than 90% on room air.
    • Oxygen level between 90-94% with a downward trend and/or signs of breathing difficulty, such as increased breathing rate, use of extra muscles to breathe, or inability to complete full sentences.
    • Need for oxygen through non-invasive methods like CPAP (Continuous Positive Airway Pressure) or BIPAP (Bi-level Positive Airway Pressure), high flow oxygen, or a non-rebreather mask.
    • Need for mechanical ventilation or ECMO (Extracorporeal Membrane Oxygenation), which are advanced methods to support breathing.
  • Must be immunocompromised, meaning having a weakened immune system due to conditions like:
    • Certain blood cancers or pre-cancerous conditions, except acute leukemia or history of lymphoma.
    • Being an organ transplant recipient, except those who had a bone marrow or solid organ transplant in the last 6 months, or experienced transplant rejection in the last 6 months.
    • HIV positive with a CD4 count less than 350 cells and on stable antiretroviral therapy.
    • Primary immunodeficiency, which is a condition present from birth that affects the immune system.
    • Autoimmune disorders like rheumatoid arthritis, lupus, vasculitis, or inflammatory bowel disease, for which the patient is being treated with systemic immunosuppressive medication.
  • Must have an elevation of 2 or more inflammatory markers above specific levels:
    • Ferritin greater than 700 ug/l.
    • LDH (Lactate Dehydrogenase) greater than 400 U/L.
    • CRP (C-reactive protein) greater than 75 mg/L.

Who Cannot Join the Study?

  • Patients who do not have a confirmed infection with SARS-CoV II (the virus that causes COVID-19).
  • Patients who are not hospitalized with moderate, severe, or critical COVID-19.
  • Patients who are not immunocompromised. This means their immune system is not weakened or less able to fight infections.
  • Patients who are not within the specified age range for the study.
  • Patients who do not meet other specific health criteria required for the study.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Lille Lille France
Centro Hospitalar Universitario Sao Joao E.P.E. Porto Portugal
Medizinische Universitaet Innsbruck Innsbruck Austria
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli Naples Italy
Université Libre de Bruxelles – Hôpital Erasme Brussels Belgium

Other Sites

Site Name City Country Status
Ospedale S G Moscati Statte Italy
University Of Milan Milan Italy
Assistance Publique Hopitaux De Paris Paris France
University Of Pecs Pecs Hungary
St. Olavs Hospital HF Trondheim Norway
University Hospital Limerick Limerick Ireland
Ospedale Fabrizio Spaziani Frosinone Italy
Ctwxhdwof Uizgavxoahxoxp Sdhnbbeuy Woluwe-Saint-Lambert Belgium
Uzshlvzuhhlalewiavswe Nxenbahtye Hw Tromsø Norway
Eetrptvowvze Svha Athens Greece
Uxvmofsgeq Op Doklnejh Debrecen Hungary
Byhymzzn Hdjlfdiv Dublin Ireland
Vdyspu dmb Rlkfb Uhvtaxedzm Hlvrmlmd Sevilla Spain
Atwlzelx Ubrhrgjfeu Hwvnjdri Lorenskog Norway
Cjwrvd Huxxzahsyo E Uwygfqhxeqiqo Dz Ciozgtm Euifir Coimbra Portugal
Sdjiwtydw Ojsxiqgn Hc Kmebrr Graalum Norway
Umfmodgerl Oa Sqsmar Szeged Hungary
Si Vzowolofoijfsrg Ulxfkypqjq Hubtcfmk Dublin Ireland
Kvvkrjhu dvh Tlugmhlbxxa Untzbqiphmio Mjvrhmtt (usx Khpfrmaie Munich Germany
Vbluh Ujfeypcamvsy Bcanoca Jette Belgium
Uutffibaav Dgzyv Strqq Da Bdirutw Brescia Italy
Fantlnxsq Pgrd Lf Irdriyoobixwn Bfigjspvf Dzn Hvhgqxuj Upqullunhurvo Ln Pnj Madrid Spain
Umivfotjtew Nlkstkxbz Mbtfjz Martin Slovakia
Fdcsoded Neujpkvnx Tyzhzm Trnava Slovakia
Bewaxs Srnmfxx Gjettum Norway
Dtwfzqx Schxlru Drammen Norway
Unhzcdhjst Gbrqzno Hylzglnb Abignhi Athens Greece
Fivtvsjl Ndrqrgefl Tcuhxyj Trencin Slovakia
Cbjetx Hsnohdqydyj Urohcxmulnfcw Arzgrp Pzomitra Amiens France
Httsfqk Sbojb Akldkie Paris France
Arblycp Sqnldohsy Uutotkmcdemli Gpdrtkpc Ifbflkvh Trieste Italy
Ceu Czzdy Rtlrparfghb Lyon France
Hrpjb Svsbblvug Hx Stavanger Norway
Vzckmrjv Htyijbzo Tuvvq Tonsberg Norway
Kzkzqida Beadndzumwey gukub Bremen Germany
Otifngmc Sygphoyoed Twufhor Cagliari Italy
Ciywov Hibqotwntxh Uqpamqhvwwxxd Db Bdlcjuqi Bordeaux France
Cjbxee Hykppitzwtn dw Lgucehxqsd Luxembourg Luxembourg
Ctevsp Hwlozizint Uuqjliinmzcrg Lylktc Ctintzp Ektadk Lisbon Portugal
Crzypl Hfjusksjjhz Uouzyyaukhklf Da Dqqsj Dijon France
Uxwccwgnzp Hfscajom Gjvidz Galway Ireland
Ocwb Uviznlijob Htebkmmz Hj Oslo Norway
Fewesufo Nllnxbecb U Sa Ayih V Beov Brno-Stred Czechia
Hxjmhebc Udvqhmrypdlqi Vnjlrm Dq Vpxyq Sevilla Spain
Gvcfnz Hfqamgdmesi Dw Lt Rzygso Dg Mbejwijw Es Sct Atuvya Mulhouse France
Choksj Rwpmubqr Cdjfwplt Dz Vmjorz Sogxyx Verona Italy
Cfjd Untudrurgt Hpprhksn Cork Ireland
Azezdkx Obeqppjzlnn Unajbuowxhlpc Ppztfncrlbp Puumm Gouvqifu Palermo Italy
Utsisqtkxq Heqvcfar Bfpctuomie Bratislava Slovakia
Udaddqrrwk Mwbet Gpdzmdy Ov Cztczjybj Catanzaro Italy
Hjyeikkl Uwpjxjqddkdtj Da Jdwi Jaen Spain
Oppmlqqq Mxnkw Swqjonn Dj Lsyvszz Legnago Italy
Ongifvvn Szpuu Myxlj Anlmboecxz Bagno A Ripoli Italy
Orexbakb Sfweb Mkich Gpwwflq Ldiokd Latina Italy
Aqmaohx Ozqjqjxymgo Ogjqknqy Rnyfydc Mkddlk Nidp Pesaro Italy
Lnslxoifnuj Dtqhduwsz Sbdnvka Ae Oslo Norway
Olojverw Cljlvxvq Mytixsf Asti Italy
Hmkvaxxj Clvxd dcp Spo Marbella Spain
Hjhtxqr Liukv Mljanjr Colombes France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Not recruiting
22.04.2022
Belgium Belgium
Not recruiting
22.04.2022
Czechia Czechia
Not recruiting
22.04.2022
France France
Not recruiting
22.04.2022
Germany Germany
Not recruiting
22.04.2022
Greece Greece
Not recruiting
22.04.2022
Hungary Hungary
Not recruiting
22.04.2022
Ireland Ireland
Not recruiting
22.04.2022
Italy Italy
Not recruiting
22.04.2022
Luxembourg Luxembourg
Not recruiting
22.04.2022
Norway Norway
Not recruiting
22.04.2022
Portugal Portugal
Not recruiting
22.04.2022
Slovakia Slovakia
Not recruiting
22.04.2022
Spain Spain
Not recruiting
22.04.2022

Trial locations

Investigated Drugs:

Baricitinib is a medication that is being studied for its potential to help patients with severe or critical COVID-19, especially those who have weakened immune systems. It works by reducing inflammation in the body, which can be a significant problem in severe COVID-19 cases. By doing so, it may help prevent the disease from getting worse and reduce the risk of death in hospitalized patients. This medication is being compared to a placebo to see if it provides any additional benefits when added to the standard care that patients are already receiving.

Investigated Diseases:

COVID-19 – COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. It primarily affects the respiratory system, leading to symptoms such as fever, cough, and difficulty breathing. The disease can progress from mild symptoms to moderate, severe, or critical states, with severe cases potentially requiring hospitalization. In moderate cases, patients may experience increased respiratory distress and require supplemental oxygen. Severe cases can lead to acute respiratory distress syndrome (ARDS), necessitating mechanical ventilation. Critical cases may involve multi-organ failure and require intensive care support.

Trial ID:
2022-500385-99-00
NCT ID:
NCT04891133
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on the Effectiveness of Osimertinib for Patients with EGFR Mutant Non-Small Cell Lung Cancer Based on TP53 Mutation Status

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy

  • Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

    Not recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium Czechia France Greece Ireland Italy +4